Mirabegron a valuable drug for management of irritative symptoms after TURBT: Study

Written By : Dr. Shravani Dali |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2021-10-04T09:00:40+05:30 | Updated On 4 Oct 2021 9:00 AM IST

Mirabegron effective for the management of irritative symptoms after transurethral resection of bladder tumours (TURBT), suggests a study published in Cancer Medicine.

Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. Its benefits are similar to antimuscarinic medication such as solifenacin or tolterodine.

A group of researchers from China conducted a study to explore the efficacy and safety of mirabegron in treating irritative symptoms induced by intravesical immunotherapy with Bacillus Calmette-Guerin (BCG) after transurethral resection of bladder tumours (TURBT).

The researchers randomly divided a total of 160 patients subjected to transurethral resection of bladder tumours (TURBT) into the mirabegron group and placebo group with 80 patients in each group. Then, the patients were administered 25 mg mirabegron or placebo daily, starting the first day after Bacillus Calmette-Guerin (BCG) infusion. The first BCG perfusion was conducted at least 2 weeks after transurethral resection of bladder tumours (TURBT). The 3-day bladder diaries were completed in all patients, 1 day before Bacillus Calmette-Guerin (BCG) perfusion, and on the 1st, 6th, and 13th days after the first Bacillus Calmette-Guerin (BCG) perfusion. Overactive bladder symptom scores were completed 1 day before Bacillus Calmette-Guerin (BCG) perfusion, and on the 6th and 13th days after the first Bacillus Calmette-Guerin (BCG) perfusion.

The results of the study are as follows:

· Symptom scores of bladder hyperactivity were significantly different between the two groups.

· Also, the frequency of nocturia, pollakiuria, micturition urgency, urinary incontinence and was significantly lower in group 1 than that in group two.

Thus, the researchers concluded that their findings demonstrate that mirabegron is a valuable clinical drug for the management of irritative symptoms after transurethral resection of bladder tumours (TURBT) with subsequent intravesical Bacillus Calmette-Guerin (BCG) perfusion.

Reference:

A study titled, "Mirabegron improves the irritative symptoms caused by BCG immunotherapy after transurethral resection of bladder tumours" by Sun K et. al published in Cancer Medicine.

DOI: 10.1002/cam4.4278

cancer medicinemirabegronbladder cancerbladder tumourturbttransurethral resection of bladder tumorsbcg immunotherapy

Source : Cancer medicine

Dr. Shravani Dali

Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751